Rubella virus vaccine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Accession Number

DB10317

Description

Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).

Type

Biotech

Groups

Approved, Investigational

Biologic Classification

Vaccines
Attenuated

Synonyms

Rubella virus (vaccine strain ra27/3) live antigen
Rubella virus live antigen, A
Rubella virus strain wistar ra 27/3 live (attenuated) antigen
Rubella virus strain wistar ra 27/3 live antigen
Rubella virus vaccine live (wistar ra 27-3 strain)
Rubella virus vaccine,live
Rubella, live attenuated
Rubivirus rubella virus wistar ra 27/3 whole

Pharmacology

Indication

Not Available

Associated Conditions

Contraindications & Blackbox Warnings

Learn about our commercial Contraindications & Blackbox Warnings data.

Learn More

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects

Learn about our commercial Adverse Effects data.

Learn More

Toxicity

Not Available

Affected organisms

Not Available

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.

Drug	Interaction
Unlock Additional Data
Abacavir	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Abacavir.
Abatacept	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Abatacept.
Acyclovir	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Acyclovir.
Adalimumab	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Adalimumab.
Adefovir dipivoxil	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Adefovir dipivoxil.
Aldesleukin	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Aldesleukin.
Alefacept	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alefacept.
Alemtuzumab	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Alemtuzumab.
Altretamine	The risk or severity of infection can be increased when Rubella virus vaccine is combined with Altretamine.
Amantadine	The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Amantadine.

Additional Data Available

Extended Description

Available for Purchase

Extended description of the mechanism of action and particular properties of each drug interaction.

Learn more

Severity

Available for Purchase

A severity rating for each drug interaction, from minor to major.

Learn more

Evidence Level

Available for Purchase

A rating for the strength of the evidence supporting each drug interaction.

Learn more

Action

Available for Purchase

An effect category for each drug interaction. Know how this interaction affects the subject drug.

Learn more

Food Interactions

Not Available

Products

International/Other Brands

Meruvax II

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
M-M-R II	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	Merck Sharp & Dohme Corp.	1971-04-21	Not applicable
M-M-R II	Rubella virus vaccine (1000 TCID50/0.5mL) + Measles virus vaccine live attenuated (1000 TCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 TCID50/0.5mL)	Powder, for solution	Subcutaneous	Merck Ltd.	1979-12-31	Not applicable
M-M-R II	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	A-S Medication Solutions	1971-04-21	Not applicable
M-M-R II	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (12500 [TCID_50]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	Physicians Total Care, Inc.	1996-08-07	2012-06-30
Priorix	Rubella virus vaccine (103.0 CCID50/0.5mL) + Measles virus vaccine live attenuated (103.0 CCID50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (103.7 CCID50/0.5mL)	Kit; Powder, for solution	Intramuscular; Subcutaneous	Glaxosmithkline Inc	1998-12-04	Not applicable
ProQuad	Rubella virus vaccine (3 log10 tcid50/0.5mL) + Measles virus vaccine live attenuated (3 log10 tcid50/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (4.3 log10 tcid50/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (3.99 log10 tcid50/0.5mL)	Powder, for solution	Subcutaneous	Merck Ltd.	2014-05-09	Not applicable
ProQuad	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	Merck Sharp & Dohme Corp.	2015-07-01	Not applicable
ProQuad	Rubella virus vaccine (1000 [TCID_50]/0.5mL) + Measles virus vaccine live attenuated (1000 [TCID_50]/0.5mL) + Mumps virus strain B level jeryl lynn live antigen (20000 [TCID_50]/0.5mL) + Varicella Zoster Vaccine (Live/attenuated) (9772 [PFU]/0.5mL)	Injection, powder, lyophilized, for suspension	Subcutaneous	Merck Sharp & Dohme Limited	2005-09-06	2018-08-31

Chemical Identifiers

UNII: 52202H034Z
CAS number: Not Available

References

General References

TITCK Product Information: R-VAC (rubella vaccine, live, attenuated) for subcutaneous injection [Link]

External Links

PubChem Substance: 347910496
RxNav: 9486

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
4	Completed	Prevention	BCG Infection / Immune Response / Reaction - Vaccine	1
4	Completed	Prevention	Chickenpox / Hepatitis A / Mumps / Rubella / Rubeola	1
4	Completed	Prevention	Encephalitis, Japanese B / Mumps / Rubella / Rubeola	1
4	Completed	Prevention	Hepatitis A Virus	1
4	Completed	Prevention	Measles Antibody Seroconversion / Rotavirus Geometric Mean Titer (GMT) / Rotavirus Immunoglobulin A (IgA) Seropositivity / Rubella Antibody Seroconversion	1
4	Completed	Prevention	Mumps / Rubella / Rubeola	2
3	Active Not Recruiting	Treatment	Pneumococcal Infection	1
3	Completed	Prevention	Acellular Pertussis / Diphtheria / Poliomyelitis / Tetanus	1
3	Completed	Prevention	Acellular Pertussis / Diphtheria / Tetanus	1
3	Completed	Prevention	Bacterial Infections / Neisseria Meningitidis / Virus Diseases	2

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Not Available

Dosage Forms

Form	Route	Strength
Injection, powder, lyophilized, for solution	Subcutaneous	1000 [CCID_50]/0.5mL
Injection, powder, lyophilized, for suspension	Subcutaneous
Injection, powder, for suspension	Intramuscular; Subcutaneous	1000 CCID50/0.5mL
Injection, powder, lyophilized, for solution	Intramuscular; Subcutaneous	1000 TCID
Injection, powder, lyophilized, for suspension	Subcutaneous	1000 [TCID_50]/0.5mL
Injection, powder, for solution	Intramuscular; Subcutaneous	103 CCID50/0.5mL
Injection, powder, for solution	Subcutaneous	103 CCID50/0.5mL
Kit; powder, for solution	Intramuscular; Subcutaneous
Injection, solution	Intramuscular; Subcutaneous	1000 CCID
Injection, powder, for solution	Intramuscular; Subcutaneous	1000 CCID
Injection, powder, lyophilized, for solution	Intramuscular; Subcutaneous	10 CCID
Injection, solution	Intramuscular; Subcutaneous	5011 CCID50/0.5mL
Injection, powder, for solution	Intramuscular; Subcutaneous	5011 CCID50/0.5mL
Injection, powder, for solution	Subcutaneous	10 CCID
Injection, powder, lyophilized, for suspension	Subcutaneous	1000 CCID_50
Injection, powder, lyophilized, for solution	Subcutaneous	10 CCID
Injection, powder, for suspension	Intramuscular; Subcutaneous	1000 [TCID_50]/0.5mL
Injection, powder, lyophilized, for suspension	Intramuscular; Subcutaneous	1000 [TCID_50]/0.5mL
Powder, for solution	Subcutaneous
Injection, powder, lyophilized, for suspension	Intramuscular; Subcutaneous	3 log10/0.5ml
Injection	Subcutaneous	0.5 ml
Injection, powder, lyophilized, for suspension	Subcutaneous	1000 CCID50/5ml
Injection	Subcutaneous	1000 CCID50/0.5mL

Prices